Clinical Outcomes of Culture-Positive Pneumonia in Solid Organ Transplant Recipients
L. Rice1, A. C. Kalil2, D. Hixson2, M. Leick3
1Monument Health, Rapid City, SD, 2University of Nebraska Medical Center, Omaha, NE, 3Nebraska Medicine, Omaha, NE
Meeting: 2021 American Transplant Congress
Abstract number: 759
Keywords: Bacterial infection, Infection, Pneumonia
Topic: Clinical Science » Infectious Disease » All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis)
Session Type: Poster Abstract
Session Date & Time: None. Available on demand.
Location: Virtual
*Purpose: The purpose of this study is to determine the differences in clinical outcomes of culture-positive pneumonia in solid organ transplant (SOT) recipients compared to non-SOT patients.
*Methods: This retrospective cohort study included adult inpatients with positive bronchoalveolar lavage (BAL) or sputum cultures. SOT patients were matched 1:2 to non-SOT patients based on age and gender. The primary outcome was in-hospital mortality. Secondary outcomes included 90-day mortality, time-to-appropriate antibiotics, antibiotic duration, days on ventilator, hospital length of stay (LOS), and hospital readmission.
*Results: This study included 73 SOT and 146 matched non-SOT patients. The average age was 54.7 years; 67.6% were male. The majority were Caucasian (87.7% vs 82.2%, p=0.3). Of the SOT patients, the majority were kidney (30.1%) and liver (20.6%) recipients. Average time post-transplant was 6.4±8 years. Regarding baseline characteristics, SOT recipients were more likely to have hypertension (72.6% vs 58.2%, p=0.04), diabetes (43.8% vs 29.5%, p=0.03), and end-stage renal disease (12.3% vs 0.7%, p=0.0001). In-hospital mortality for SOT recipients was not statistically significantly different compared to non-SOT (27.4% vs 18.5%, p=0.13). Hospital LOS was longer for SOT recipients (34.9 vs 25.3 days, p=0.03) and time to readmission was shorter (19.6 vs 26.6 days, p=0.03). Other secondary outcomes were similar between groups. In terms of cultures, SOT recipients were more likely to have BAL cultures (42.5% vs 28.1%, p=0.03). The most common organisms were Pseudomonas aeruginosa (31.5% vs 23.3%, p=0.09), Methicillin-sensitive Staphylococcus aureus (9.6% vs 22.6%, p=0.045), Methicillin-resistant S. aureus (13% vs 13.7%, p=0.68), Klebsiella pneumonia (6.8% vs 11%, p=0.45), and Escherichia coli (9.6% vs 8.9%, p=0.69). The most common initial and appropriate antibiotics were vancomycin, piperacillin-tazobactam, and cefepime. Combination antibiotics were initiated in most patients (64.4 vs 63.7%, p=0.92). Appropriate antibiotic duration was similar (9.1 vs 13.2 days, p=0.31), but SOT recipients were more likely to not receive appropriate antibiotics (21.9% vs 11.6%, p=0.03).
*Conclusions: In-hospital mortality in SOT recipients was not significantly different from that in non-SOT patients. SOT recipients had a significantly longer hospital LOS, shorter time to readmission and were less likely to receive appropriate antibiotics.
To cite this abstract in AMA style:
Rice L, Kalil AC, Hixson D, Leick M. Clinical Outcomes of Culture-Positive Pneumonia in Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-outcomes-of-culture-positive-pneumonia-in-solid-organ-transplant-recipients/. Accessed November 21, 2024.« Back to 2021 American Transplant Congress